Comparative Effectiveness of Different Oral Antibiotics Regimens for Treatment of Urinary Tract Infection in Outpatients: An Analysis of National Representative Claims Database

AbstractThere are very limited data on the postmarketing outcome comparison of different guideline antibiotic regimens for patients with urinary tract infections (UTIs).We carried out a population-based comparative effectiveness study from year 2000 through 2009, using the administrative data of 2 million patients from the National Health Informatics Project of Taiwan. Treatment failure was defined as either hospitalization or emergency department visits for UTI. Odd ratios were computed using conditional logistic regression models matched on propensity score.We identified 73,675 individuals with UTI, of whom 54,796 (74.4%) received trimethoprim–sulfamethoxazole (TMP-SMX), 4184 (5.7%) received ciprofloxacin, 3142 (4.3%) received levofloxacin, 5984 (8.1%) received ofloxacin, and 5569 (7.6%) received norfloxacin. Compared with TMP-SMX, the composite treatment failure was significantly lowered for norfloxacin in propensity score (PS) matching analyses (OR, 0.73; 95% CI, 0.54–0.99). Both norfloxacin (PS-matched OR, 0.68; 95% CI, 0.47–0.98) and ofloxacin (PS-matched OR, 0.70; 95% CI, 0.49–0.99) had significantly lowered composite treatment failure rate when compared with ciprofloxacin. Subgroup analysis suggested that both norfloxacin and ofloxacin were more effective in female patients without complications (W/O indwelling catheters, W/O bedridden status and W/O spinal cord injury), when compared with either TMP-SMX or ciprofloxacin.Among outpatients receiving oral fluoroquinolone therapy for UTIs, there was evidence of superiority of norfloxacin or ofloxacin over ciprofloxacin or TMP-SMX in terms of treatment failure. Given the observational nature of this study and regional difference in antibiotic resistance patterns, more studies are required to validate our results.

[1]  L. Preheim,et al.  Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections , 1988, Antimicrobial Agents and Chemotherapy.

[2]  G. ter Riet,et al.  Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials. , 2012, Family practice.

[3]  A. Mehlhorn,et al.  Infectious Diseases: Safety Concerns with Fluoroquinolones , 2007, The Annals of pharmacotherapy.

[4]  R. Simes,et al.  Clinical trials and "real-world" medicine. Trial evidence best informs real-world medicine when it is relevant to the clinical problem. , 2002, The Medical journal of Australia.

[5]  C. Metge,et al.  Use of administrative healthcare claims to examine the effectiveness of trimethoprim-sulfamethoxazole versus fluoroquinolones in the treatment of community-acquired acute pyelonephritis in women. , 2004, The Journal of antimicrobial chemotherapy.

[6]  D. Hooper,et al.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis , 1989, Antimicrobial Agents and Chemotherapy.

[7]  D. Talan,et al.  Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Simes Rj,et al.  Clinical trials and "real-world" medicine. Trial evidence best informs real-world medicine when it is relevant to the clinical problem. , 2002 .

[9]  R. Echols,et al.  A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. , 1999, The American journal of medicine.

[10]  M. Lai,et al.  The risk of developing non‐melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10‐year, population‐based cohort study , 2012, International journal of dermatology.

[11]  T. Griebling Urologic diseases in America project: trends in resource use for urinary tract infections in women. , 2005, The Journal of urology.

[12]  Harlan M Krumholz,et al.  Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. , 2003, American heart journal.

[13]  P. Hsueh,et al.  Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan , 2005, International Journal of Antimicrobial Agents.

[14]  Sanjay Saint,et al.  Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[16]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[17]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Kim,et al.  A Recent Study on the Antimicrobial Sensitivity of the Organisms that Cause Urinary Tract Infection , 2007 .

[19]  P. L. Gottlieb Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection. , 1995, Clinical therapeutics.

[20]  W. Ko,et al.  Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections , 2013, Expert opinion on pharmacotherapy.

[21]  Chun-Ying Wu,et al.  Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. , 2013, Journal of the American Academy of Dermatology.

[22]  J. Reuning-Scherer,et al.  Comparison of Ciprofloxacin (7 Days) and Trimethoprim-Sulfamethoxazole (14 Days) for Acute Uncomplicated Pyelonephritis in Women , 2000 .

[23]  Hans H. Liu,et al.  Appropriate antibiotic treatment of genitourinary infections in hospitalized patients. , 2005, The American journal of medicine.

[24]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Bergman Urinary tract infections in women , 1991, Current opinion in obstetrics & gynecology.

[26]  D. Scholes,et al.  Population-based epidemiologic analysis of acute pyelonephritis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Chun-Eng Liu,et al.  Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). , 2012, International journal of antimicrobial agents.

[28]  T. Lauderdale,et al.  The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. , 2004, Diagnostic microbiology and infectious disease.

[29]  Betsy Foxman,et al.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. , 2002, The American journal of medicine.

[30]  A. Almeida,et al.  Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009) , 2013, BMC Infectious Diseases.

[31]  B. Foxman,et al.  Acute pyelonephritis among adults , 2012, PharmacoEconomics.

[32]  J. Hughes,et al.  A prospective study of risk factors for symptomatic urinary tract infection in young women. , 1996, The New England journal of medicine.

[33]  G. Kahlmeter,et al.  Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. , 2012, International journal of antimicrobial agents.

[34]  M. Lai,et al.  Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus , 2012, Hepatology.

[35]  K. Naber,et al.  Which fluoroquinolones are suitable for the treatment of urinary tract infections? , 2001, International journal of antimicrobial agents.

[36]  A. Masquelier,et al.  A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis. , 1992, The American journal of medicine.

[37]  N. Nagelkerke,et al.  Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. , 2000, The Journal of antimicrobial chemotherapy.

[38]  T. Louie,et al.  Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole , 1994, Antimicrobial Agents and Chemotherapy.